reports
- Oliver Metzger
- Thomas Zlowodzki
- Oliver Metzger
- Thomas Zlowodzki
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
- Amira Manai
- Gautier Le Bihan
- Amira Manai
- Gautier Le Bihan
Abivax Presents First Quarter 2025 Financial Results
Abivax Presents First Quarter 2025 Financial Results Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial results for the quarter ended March 31, 2025. Abivax provided the following updates on its business...
- Antoine Lebourgeois
- Aurelien Deside
GTT : Notice regarding availability of explanatory documentation relat...
GTT : Notice regarding availability of explanatory documentation related to the combined shareholders' meeting to be held on June 11, 2025 Terms of availability of preparatory documents for the combined general meeting of shareholders on June 11, 2025 Saint-Rémy-lès-Chevreuse – May 20, 2025. GTT (Gaztransport et Technigaz) informs its shareholders that the combined (ordinary and extraordinary) general meeting of shareholders will be held on Wednesday June 11, 2025 at 3:00 pm. The notice of meeting, including the agenda and the draft resolutions as well as the conditions and modalities of ...
GTT : Modalités de mise à disposition des documents préparatoires à l'...
GTT : Modalités de mise à disposition des documents préparatoires à l'assemblée générale mixte des actionnaires du 11 juin 2025 Modalités de mise à disposition des documents préparatoires à l’assemblée générale mixte des actionnaires du 11 juin 2025 Saint-Rémy-lès-Chevreuse – Le 20 mai 2025. GTT (Gaztransport et Technigaz) informe ses actionnaires que l’assemblée générale mixte (ordinaire et extraordinaire) des actionnaires se tiendra le mercredi 11 juin 2025 à 15 heures. L’avis de réunion, comportant l’ordre du jour et les projets de résolutions ainsi que les conditions et modalités de p...
- Antoine Lebourgeois
Ekinops adds SSE capabilities with Olfeo buyout
Ekinops has signed an agreement to acquire Olfeo, a French cybersecurity software vendor focused on Security Service Edge (SSE) solutions. The deal adds EUR6.3m in ARR (>20% EBITDA margin) and is fully cash-funded. While the price remains undisclosed, Ekinops’ post-transaction net cash position
GTT: Monthly disclosure of the total number of voting rights and share...
GTT: Monthly disclosure of the total number of voting rights and shares composing the share capital Monthly disclosure of the total number of voting rights and shares composing the share capital Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés Financiers Saint-Rémy-lès-Chevreuse, May 9, 2025 DateTotal number of sharesTheoretical total number of voting rights1Net total number of voting rights2April 30, 202537,117,77237,117,77237,030,337 Investor Relations Contact / 87 1 Calculated on th...
GTT : Information mensuelle relative au nombre total de droits de vote...
GTT : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Articles L. 233-8-II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers Saint-Rémy-lès-Chevreuse, le 9 mai 2025 DateNombre total d’actions composant le capitalNombre total de droits de vote théoriques1Nombre total de droits de vote nets230 avril 202537.117.77237.117.77237.030.337 Contact Relations Investisseurs : / 87 ...
- Nicolas David
- Thomas Zlowodzki
EVT EVOTEC SE
ISS ISS A/S
MTU MANITOU BF SA
ELG ELMOS SEMICONDUCTOR SE
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
PNL POSTNL NV
G24 SCOUT24 AG
NANO NANOBIOTIX SA
ELIS ELIS SA
COFA COFACE SA
IDR INDRA SISTEMAS S.A. CLASS A
SAE SHOP APOTHEKE EUROPE NV
RUI RUBIS SCA
SANT S&T AG
TMV TEAMVIEWER AG
- Nicolas David
- Thomas Zlowodzki
EVT EVOTEC SE
ISS ISS A/S
MTU MANITOU BF SA
ELG ELMOS SEMICONDUCTOR SE
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
PNL POSTNL NV
G24 SCOUT24 AG
NANO NANOBIOTIX SA
ELIS ELIS SA
COFA COFACE SA
IDR INDRA SISTEMAS S.A. CLASS A
SAE SHOP APOTHEKE EUROPE NV
RUI RUBIS SCA
SANT S&T AG
TMV TEAMVIEWER AG
- Jean-François Granjon
- Jean-François Granjon
GTT - Acquisition de Danelec - Communiqué de presse
GTT - Acquisition de Danelec - Communiqué de presse GTT franchit un cap décisif dans le domaine du Digital avec l’acquisition de Danelec, un leader mondial de la collecte et de l’analyse des données maritimes Une acquisition qui propulse GTT au premier rang mondial du marché de la gestion de la performance des naviresUn fort potentiel de croissance et de synergiesUn effet relutif dès la première année sur le résultat net par action du GroupeUne valeur d’entreprise de 194 millions d’euros, soit environ 15 fois l’EBITDA 2024/20251 avant synergies Paris, le 5 mai 2025 – GTT annonce la signa...
GTT - Acquisition of Danelec - Press Release
GTT - Acquisition of Danelec - Press Release GTT takes a decisive step forward in the Digital sector with the acquisition of Danelec, a global leader in the collection and analysis of maritime data An acquisition that positions GTT as the world’s leading player in the vessel performance management market Significant growth and synergy potentialAn accretive impact on the Group's earnings per share from year oneAn enterprise value of 194 million euros, representing approximately 15 times the 2024/20251 EBITDA before synergies Paris – May 5, 2025 – GTT announces the signing of an agreement w...
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trial...
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%.Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week mainten...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.